Antiviral inhalation medicinal product based on interferon alpha-2b: A study of efficacy, subchronic toxicity, and toxicokinetics in rodents

INTRODUCTION. Developing high-dose interferon-based medicinal products (MPs) is particularly relevant for effective causal treatment of acute respiratory viral infections, influenza, and COVID-19 coronavirus infection. Inhalation drops both act directly on mucous membranes and stimulate powerful immune response and increased safety profile. In 2021, a new medicinal product, interferon alpha-2b-based inhalation drops, was developed to treat influenza and acute respiratory viral infections of various aetiologies.

AIM. This study aimed to assess preclinical efficacy, subchronic toxicity, and toxicokinetics of a new MP based on interferon alpha-2b and administered by inhalation.

MATERIALS AND METHODS. The new MP is based on human recombinant interferon alpha-2b. Its efficacy was studied on female BALB/c mice. The animals inhaled 3 mL of the investigational product for 10 minutes twice a day for 8 days. Animals were infected with A(H1N1)pdm2009 on Day 2 of inhalation. The dynamics of body weight and mortality, as well as influenza titre in the murine lung tissues, were evaluated 4 days after infection. MP toxicity was studied on white non-linear rats of both sexes. MP was administered using an inhaler once a day for 7 weeks at doses exceeding human therapeutic dose by 5.3 and 53 times. Pathomorphological and histopathological examination was performed on Days 29 and 43 of administration. Haematological and biochemical blood parameters, heart rate, and behavioural functions were measured prior to administration, 4 weeks into administration, and 2 weeks after the last administration. Toxicokinetics was studied on satellite groups of male rats; administration scheme was similar to toxicity studies.

RESULTS. Experiments showed that inhalation of investigational product at 923,000 IU/kg/day twice a day for 8 days inhibited A(H1N1)pdm2009 replication in the murine lungs, significantly reduced animal mortality and weight loss, and increased animal life expectancy 1.35–1.5-fold. The study doses showed no pronounced toxic, local irritant or systemic effect.

CONCLUSIONS. The inhalation investigational product has shown its efficacy and safety in preclinical studies on rodents.

1. Gattarello S, Rello J. Severe viral pneumonia in adults: what is important for the ICU physician? Hosp Pract. 2017;45(4):131–4. https://doi.org/10.1080/21548331.2017.1345280

2. Yun KW, Wallihan R, Juergensen A, et al. Community-acquired pneumonia in children: Myths and facts. Am J Perinatol. 2019;36(S 02):S54–7. https://doi.org/10.1055/s-0039-1691801

3. Wang Z, Ma W, Zheng X, et al. Household transmission of SARS-CoV-2. J Infect. 2020;81(1):179–82. https://doi.org/10.1016/j.jinf.2020.03.040

4. Li XG, Chen J, Wang W, et al. Oseltamivir treatment for influenza during the flu season of 2018–2019: A longitudinal study. Front Microbiol. 2022;13:865001. https://doi.org/10.3389/fmicb.2022.865001

5. Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https://doi.org/10.1038/s41392-021-00791-1

6. Haque SJ, Williams BR. Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-alpha. J Biol Chem. 1994;269(30):19523–9. PMID: 8034722

7. Smart A, Gilmer O, Caliskan N. Translation inhibition mediated by interferon-stimulated genes during viral infections. Viruses. 2024;16(7):1097. https://doi.org/10.3390/v16071097

8. Fu B, Wang D, Shen X, et al. Immunomodulation induced during interferon-α therapy impairs the anti-HBV immune response through CD24+CD38hi B cells. Front Immunol. 2020;11:591269. https://doi.org/10.3389/fimmu.2020.591269

9. Schuhenn J, Meister TL, Todt D, et al. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2022;119(8):e2111600119. https://doi.org/10.1073/pnas.2111600119

10. Mulder K, Patel AA, Kong WT, et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity. 2021;54(8):1883–900.e5. https://doi.org/10.1016/j.immuni.2021.07.007

11. Brice D, Figgins E, Yu F, et al. Type I interferon and interferon-­stimulated gene expression in oral epithelial cells. Mol Oral Microbiol. 2019;34(6):245–53. https://doi.org/10.1111/omi.12270

12. Leneva IА, Leonova EI, Маkhmudоvа NR, et al. Experimental model of secondary bacterial pneumonia after influenza. Problems of Virology. 2015;60(5):27–31 (In Russ.). EDN: UKSIAN

13. Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression — a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics. 2006;7:123. https://doi.org/10.1186/1471-2105-7-123

14. Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020;11:1061. https://doi.org/10.3389/fimmu.2020.01061

15. Jiang R, Han B, Song M, et al. Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial. J Inflamm. 2020;17:19. https://doi.org/10.1186/s12950-020-00249-1